

# Benjamin M Ellingson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3719327/publications.pdf>

Version: 2024-02-01

215  
papers

9,670  
citations

44444

50  
h-index

54771

88  
g-index

215  
all docs

215  
docs citations

215  
times ranked

11979  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. <i>NMR in Biomedicine</i> , 2023, 36, .	1.6	7
2	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). <i>Brain Imaging and Behavior</i> , 2022, 16, 239-251.	1.1	5
3	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2022, 24, 1020-1028.	0.6	12
4	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. <i>Neuro-Oncology</i> , 2022, 24, 770-778.	0.6	28
5	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. <i>Scientific Reports</i> , 2022, 12, 1078.	1.6	5
6	Recovery of Supraspinal Microstructural Integrity and Connectivity in Patients Undergoing Surgery for Degenerative Cervical Myelopathy. <i>Neurosurgery</i> , 2022, 90, 447-456.	0.6	2
7	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. <i>Frontiers in Oncology</i> , 2022, 12, 849993.	1.3	1
8	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. <i>Neuro-Oncology</i> , 2022, 24, 1219-1229.	0.6	9
9	Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. <i>Neurotherapeutics</i> , 2022, 19, 1855-1868.	2.1	1
10	Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life. <i>CNS Oncology</i> , 2022, 11, CNS84.	1.2	2
11	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. <i>Cancers</i> , 2022, 14, 2520.	1.7	2
12	Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks. <i>Tomography</i> , 2022, 8, 1437-1452.	0.8	0
13	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2078-TPS2078.	0.8	3
14	Characterizing malignant transformation in patients with IDH-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2065-2065.	0.8	0
15	Evaluation of the response assessment criteria in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2020-2020.	0.8	0
16	Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance) Tj ETQq0 0 0 rgBTQ0 Overlock 10 Tf 50 1		
17	A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2043-2043.	0.8	0
18	Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. <i>Journal of Neuro-Oncology</i> , 2022, 159, 509-518.	1.4	8

#	ARTICLE	IF	CITATIONS
19	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. <i>Neuro-Oncology</i> , 2021, 23, 189-198.	0.6	11
20	Voxelwise and Patientwise Correlation of <sup>18</sup> F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 319-325.	2.8	13
21	Influence of phosphate concentration on amine, amide, and hydroxyl CEST contrast. <i>Magnetic Resonance in Medicine</i> , 2021, 85, 1062-1078.	1.9	7
22	Minimizing echo and repetition times in magnetic resonance imaging using a double half-echo k-space acquisition and low-rank reconstruction. <i>NMR in Biomedicine</i> , 2021, 34, e4458.	1.6	3
23	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021, 63, 857-868.	1.1	7
24	A physical phantom for amine chemical exchange saturation transfer (CEST) MRI. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021, 34, 569-580.	1.1	2
25	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab082.	0.4	2
26	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	0.6	68
27	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021, 21, 27.	1.2	13
28	Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. <i>Radiotherapy and Oncology</i> , 2021, 156, 258-265.	0.3	18
29	Preferential tumor localization in relation to <sup>18</sup> F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	1.4	2
30	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	3.2	24
31	Detection of cerebral reorganization associated with degenerative cervical myelopathy using diffusion spectral imaging (DSI). <i>Journal of Clinical Neuroscience</i> , 2021, 86, 164-173.	0.8	7
32	ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma. <i>Data in Brief</i> , 2021, 35, 106950.	0.5	3
33	Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia. <i>Schizophrenia Research</i> , 2021, 231, 179-188.	1.1	6
34	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1022-1029.	1.2	5
35	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	3.2	112
36	Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. <i>Scientific Reports</i> , 2021, 11, 15011.	1.6	10

#	ARTICLE	IF	CITATIONS
37	Supraspinal functional and structural plasticity in patients undergoing surgery for degenerative cervical myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2021, , 1-9.	0.9	4
38	Sodium MR Neuroimaging. <i>American Journal of Neuroradiology</i> , 2021, 42, 1920-1926.	1.2	9
39	Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 395-403.	1.0	2
40	Sex-Dependent Cortical Volume Changes in Patients with Degenerative Cervical Myelopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3965.	1.0	3
41	A study of 3D radial density adapted trajectories for sodium imaging. <i>Magnetic Resonance Imaging</i> , 2021, 83, 89-95.	1.0	1
42	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	0.6	59
43	Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. <i>Microbiome</i> , 2021, 9, 236.	4.9	34
44	“Aerobic glycolytic imaging” of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2021, 32, 102882.	1.4	8
45	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). <i>Neuro-Oncology</i> , 2020, 22, 705-717.	0.6	47
46	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	0.6	23
47	Compensatory brainstem functional and structural connectivity in patients with degenerative cervical myelopathy by probabilistic tractography and functional MRI. <i>Brain Research</i> , 2020, 1749, 147129.	1.1	14
48	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020, 10, 11922.	1.6	23
49	Focal cortical dysplasia imaging discrepancies between MRI and FDG-PET: Unique association with temporal lobe location. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 81, 180-185.	0.9	6
50	Response to Letter to Editor. <i>Neuro-Oncology</i> , 2020, 22, 1706-1707.	0.6	1
51	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	1.4	5
52	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	1.6	13
53	Novel tonometer device distinguishes brain stiffness in epilepsy surgery. <i>Scientific Reports</i> , 2020, 10, 20978.	1.6	4
54	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020, 87, 931-938.	0.6	14

#	ARTICLE	IF	CITATIONS
55	Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 222, 397-410.	1.1	10
56	Ivrosidenib in Isocitrate Dehydrogenase 1 Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	0.8	167
57	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1262-1275.	0.6	109
58	Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2020, 22, 1658-1666.	0.6	27
59	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. <i>Journal of Neuro-Oncology</i> , 2020, 147, 643-652.	1.4	5
60	Pathophysiology, classification, and MRI parallels in microvascular disease of the heart and brain. <i>Microcirculation</i> , 2020, 27, e12648.	1.0	6
61	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	0.6	131
62	Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 147, 135-145.	1.4	12
63	First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 1820-1828.	3.2	54
64	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. <i>Neuro-Oncology</i> , 2020, 22, 1822-1830.	0.6	23
65	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 3135-3144.	3.2	7
66	Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas. <i>Clinical Nuclear Medicine</i> , 2020, 45, e505-e511.	0.7	4
67	The Path Forward: The Standardized Brain Tumor Imaging Protocol (BTIP) for Multicenter Trials. , 2020, , 267-282.		0
68	Contrast-Enhanced T1-Weighted Digital Subtraction for Increased Lesion Conspicuity and Quantifying Treatment Response in Malignant Gliomas. , 2020, , 49-60.		0
69	Early seizures and temporal lobe trauma predict post-traumatic epilepsy: A longitudinal study. <i>Neurobiology of Disease</i> , 2019, 123, 115-121.	2.1	91
70	Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. <i>CNS Oncology</i> , 2019, 8, CNS35.	1.2	7
71	Spinal Cord Perfusion MR Imaging Implicates Both Ischemia and Hypoxia in the Pathogenesis of Cervical Spondylosis. <i>World Neurosurgery</i> , 2019, 128, e773-e781.	0.7	32
72	Neck disability in patients with cervical spondylosis is associated with altered brain functional connectivity. <i>Journal of Clinical Neuroscience</i> , 2019, 69, 149-154.	0.8	9

#	ARTICLE	IF	CITATIONS
73	On the promise of artificial intelligence for standardizing radiographic response assessment in gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1346-1347.	0.6	3
74	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019, 40, 979-986.	1.2	24
75	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	0.6	28
76	Probabilistic independent component analysis of dynamic susceptibility contrast perfusion MRI in metastatic brain tumors. <i>Cancer Imaging</i> , 2019, 19, 14.	1.2	7
77	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	1.6	32
78	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	1.4	28
79	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
80	pH-weighted molecular MRI in human traumatic brain injury (TBI) using amine proton chemical exchange saturation transfer echoplanar imaging (CEST EPI). <i>NeuroImage: Clinical</i> , 2019, 22, 101736.	1.4	19
81	Advanced Imaging in the Evaluation of Migraine Headaches. <i>Neuroimaging Clinics of North America</i> , 2019, 29, 301-324.	0.5	20
82	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi29.	0.6	17
83	Selective middle cerebral artery occlusion in the rabbit: Technique and characterization with pathologic findings and multimodal MRI. <i>Journal of Neuroscience Methods</i> , 2019, 313, 6-12.	1.3	4
84	Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. <i>Neuro-Oncology Practice</i> , 2019, 6, 103-111.	1.0	3
85	Alterations in Cortical Thickness and Subcortical Volume are Associated With Neurological Symptoms and Neck Pain in Patients With Cervical Spondylosis. <i>Neurosurgery</i> , 2019, 84, 588-598.	0.6	26
86	Understanding brain penetrance of anticancer drugs. <i>Neuro-Oncology</i> , 2018, 20, 589-596.	0.6	12
87	18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. <i>Journal of Neuro-Oncology</i> , 2018, 139, 399-409.	1.4	32
88	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018, 20, 1525-1535.	0.6	15
89	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	0.6	24
90	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	0.6	64

#	ARTICLE	IF	CITATIONS
91	Simultaneous p<sup>H</sup>-sensitive and oxygen-sensitive <sup>MRI</sup> of human gliomas at 3<sup>T</sup> using multi-echo amine proton chemical exchange saturation transfer spin-echo gradient echo echo-planar imaging (<sup>CEST</sup>SAGE-EPI). Magnetic Resonance in Medicine, 2018, 80, 1962-1978.	1.9	38
92	Disease-Related Microstructural Differences in the Brain in Women With Provoked Vestibulodynia. Journal of Pain, 2018, 19, 528.e1-528.e15.	0.7	15
93	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. American Journal of Neuroradiology, 2018, 39, 43-45.	1.2	15
94	Reproducibility, temporal stability, and functional correlation of diffusion MR measurements within the spinal cord in patients with asymptomatic cervical stenosis or cervical myelopathy. Journal of Neurosurgery: Spine, 2018, 28, 472-480.	0.9	16
95	Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 454-462.	1.1	18
96	Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro-Oncology, 2018, 20, 457-471.	0.6	44
97	Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. Neuro-Oncology, 2018, 20, 557-566.	0.6	24
98	Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study. PLoS ONE, 2018, 13, e0206807.	1.1	8
99	Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Scientific Reports, 2018, 8, 14429.	1.6	22
100	Resting-State Functional Magnetic Resonance Imaging Connectivity of the Brain Is Associated with Altered Sensorimotor Function in Patients with Cervical Spondylosis. World Neurosurgery, 2018, 119, e740-e749.	0.7	23
101	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2018, 139, 651-659.	1.4	25
102	ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS ONE, 2018, 13, e0198548.	1.1	21
103	Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. Tomography, 2018, 4, 123-137.	0.8	16
104	Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology, 2017, 19, now189.	0.6	65
105	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 228-234.	0.6	77
106	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics, 2017, 14, 307-320.	2.1	294
107	Evaluation of Encephaloduroarteriosynangiosis Efficacy Using Probabilistic Independent Component Analysis Applied to Dynamic Susceptibility Contrast Perfusion MRI. American Journal of Neuroradiology, 2017, 38, 507-514.	1.2	8
108	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade III diffuse gliomas. Journal of Neuro-Oncology, 2017, 134, 177-188.	1.4	118

#	ARTICLE	IF	CITATIONS
109	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. <i>Journal of Neuro-Oncology</i> , 2017, 134, 495-504.	1.4	160
110	Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic-Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas. <i>American Journal of Neuroradiology</i> , 2017, 38, 478-484.	1.2	39
111	Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. <i>European Journal of Radiology</i> , 2017, 97, 31-36.	1.2	42
112	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10220-10225.	3.3	79
113	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	3.2	53
114	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. <i>Neuro-Oncology</i> , 2017, 19, 89-98.	0.6	68
115	SU78. Intracortical Myelination Within the Frontal Lobe as a Potential Biomarker for Therapeutic Effectiveness in Antipsychotics Using MRI With Selective Myelin-Lipid Suppression at 1.5 and 3 T. <i>Schizophrenia Bulletin</i> , 2017, 43, S189-S189.	2.3	0
116	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. <i>American Journal of Neuroradiology</i> , 2016, 37, 1440-1446.	1.2	39
117	Multisite, multimodal neuroimaging of chronic urological pelvic pain: Methodology of the MAPP Research Network. <i>NeuroImage: Clinical</i> , 2016, 12, 65-77.	1.4	29
118	Dynamic Susceptibility Contrast MR Imaging in Glioma. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 649-670.	0.6	43
119	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T. <i>NMR in Biomedicine</i> , 2016, 29, 1563-1576.	1.6	51
120	Brain white matter changes associated with urological chronic pelvic pain syndrome: multisite neuroimaging from a MAPP case-control study. <i>Pain</i> , 2016, 157, 2782-2791.	2.0	43
121	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. <i>Cancer</i> , 2016, 122, 1718-1727.	2.0	47
122	ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. <i>Clinical Cancer Research</i> , 2016, 22, 5079-5086.	3.2	99
123	Assessing variability in brain tumor segmentation to improve volumetric accuracy and characterization of change. , 2016, 2016, 380-383.		4
124	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC) MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1229-1237.	1.9	27
125	Topographical Distribution of Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex. <i>Journal of Child Neurology</i> , 2016, 31, 636-645.	0.7	10
126	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	3.2	62



#	ARTICLE	IF	CITATIONS
127	Pain and Interoception Imaging Network (PAIN): A multimodal, multisite, brain-imaging repository for chronic somatic and visceral pain disorders. <i>NeuroImage</i> , 2016, 124, 1232-1237.	2.1	26
128	Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma. <i>Cancer Science</i> , 2016, 107, 1110-1116.	1.7	16
129	Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 868-879.	1.2	27
130	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. <i>NeuroImage: Clinical</i> , 2015, 9, 617-624.	1.4	23
131	Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. <i>International Journal of Oncology</i> , 2015, 46, 1883-1892.	1.4	57
132	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). <i>Neuro-Oncology</i> , 2015, 17, v158.4-v159.	0.6	70
133	Novel Magnetic Resonance Imaging Techniques in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 137-146.	0.7	2
134	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 127-136.	0.7	20
135	Unique Microstructural Changes in the Brain Associated with Urological Chronic Pelvic Pain Syndrome (UCPPS) Revealed by Diffusion Tensor MRI, Super-Resolution Track Density Imaging, and Statistical Parameter Mapping: A MAPP Network Neuroimaging Study. <i>PLoS ONE</i> , 2015, 10, e0140250.	1.1	64
136	DTI of tuber and perituberal tissue can predict epileptogenicity in tuberous sclerosis complex. <i>Neurology</i> , 2015, 85, 2011-2015.	1.5	33
137	A novel bicompartamental mathematical model of glioblastoma multiforme. <i>International Journal of Oncology</i> , 2015, 46, 825-832.	1.4	5
138	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. <i>Oncology Reports</i> , 2015, 33, 2883-2888.	1.2	5
139	Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 506.	2.0	114
140	Nitroxoline induces apoptosis and slows glioma growth in vivo. <i>Neuro-Oncology</i> , 2015, 17, 53-62.	0.6	41
141	Brain White Matter Abnormalities in Female Interstitial Cystitis/Bladder Pain Syndrome: A MAPP Network Neuroimaging Study. <i>Journal of Urology</i> , 2015, 194, 118-126.	0.2	54
142	Patterns of brain structural connectivity differentiate normal weight from overweight subjects. <i>NeuroImage: Clinical</i> , 2015, 7, 506-517.	1.4	67
143	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 122, 497-505.	1.4	37
144	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015, 17, 434-442.	1.3	28

#	ARTICLE	IF	CITATIONS
145	Correlation between degree of subvoxel spinal cord compression measured with super-resolution tract density imaging and neurological impairment in cervical spondylotic myelopathy. <i>Journal of Neurosurgery: Spine</i> , 2015, 22, 631-638.	0.9	25
146	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. <i>Clinical Cancer Research</i> , 2015, 21, 4373-4383.	3.2	27
147	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
148	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015, 17, 1514-1524.	0.6	96
149	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	0.6	346
150	Standardized Brain Tumor Imaging Protocol for Clinical Trials. <i>American Journal of Neuroradiology</i> , 2015, 36, E65-E66.	1.2	4
151	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. <i>CNS Oncology</i> , 2015, 4, 247-256.	1.2	16
152	Advances in MR imaging for cervical spondylotic myelopathy. <i>European Spine Journal</i> , 2015, 24, 197-208.	1.0	47
153	Prediction of Neurological Impairment in Cervical Spondylotic Myelopathy using a Combination of Diffusion MRI and Proton MR Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139451.	1.1	46
154	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2015, 1, 37-43.	0.8	12
155	Diffusion-Weighted Imaging of the Spinal Cord. , 2014, , 123-145.		6
156	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. <i>Neuro-Oncology</i> , 2014, 16, 414-420.	0.6	82
157	Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. <i>Cancer Imaging</i> , 2014, 14, 31.	1.2	21
158	Impact of imaging measurements on response assessment in glioblastoma clinical trials. <i>Neuro-Oncology</i> , 2014, 16, vii24-vii35.	0.6	32
159	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014, 16, vii36-vii47.	0.6	41
160	Emerging techniques and technologies in brain tumor imaging. <i>Neuro-Oncology</i> , 2014, 16, vii12-vii23.	0.6	41
161	Pros and cons of current brain tumor imaging. <i>Neuro-Oncology</i> , 2014, 16, vii2-vii11.	0.6	56
162	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. <i>Neuro-Oncology</i> , 2014, 16, v25-v25.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. <i>Radiology</i> , 2014, 271, 200-210.	3.6	150
164	Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3550-3559.	3.2	115
165	Regional and Voxel-Wise Comparisons of Blood Flow Measurements Between Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) and Arterial Spin Labeling (ASL) in Brain Tumors. <i>Journal of Neuroimaging</i> , 2014, 24, 23-30.	1.0	45
166	Diffusion tensor imaging predicts functional impairment in mild-to-moderate cervical spondylotic myelopathy. <i>Spine Journal</i> , 2014, 14, 2589-2597.	0.6	67
167	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. <i>Journal of Neuro-Oncology</i> , 2014, 116, 373-379.	1.4	95
168	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 551-558.	1.4	12
169	Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Journal of Neuro-Oncology</i> , 2014, 116, 601-608.	1.4	6
170	Imaging Techniques in Spinal Cord Injury. <i>World Neurosurgery</i> , 2014, 82, 1351-1358.	0.7	37
171	Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2007-2007.	0.8	3
172	Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 112, 257-266.	1.4	13
173	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. <i>CNS Oncology</i> , 2013, 2, 33-47.	1.2	17
174	Diffusion tensor imaging detects microstructural reorganization in the brain associated with chronic irritable bowel syndrome. <i>Pain</i> , 2013, 154, 1528-1541.	2.0	134
175	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. <i>PET Clinics</i> , 2013, 8, 201-217.	1.5	8
176	Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. <i>PET Clinics</i> , 2013, 8, 163-182.	1.5	4
177	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. <i>Neuro-Oncology</i> , 2013, 15, 370-381.	0.6	97
178	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. <i>Neuro-Oncology</i> , 2013, 15, 626-634.	0.6	91
179	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Neuro-Oncology</i> , 2013, 15, 382-390.	0.6	38
180	Structural changes in functional gastrointestinal disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 200-202.	8.2	7

#	ARTICLE	IF	CITATIONS
181	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 333-343.	0.6	74
182	<sup>18</sup> F-Deoxy- <sup>18</sup> F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab. <i>Journal of Nuclear Medicine</i> , 2012, 53, 29-36.	2.8	122
183	<sup>18</sup> F-FDOPA and <sup>18</sup> F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. <i>Neuro-Oncology</i> , 2012, 14, 1079-1089.	0.6	99
184	Diffusion Tensor Magnetic Resonance Tractography of the Prostate: Feasibility for Mapping Periprostatic Fibers. <i>Urology</i> , 2012, 80, 219-223.	0.5	34
185	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. <i>NeuroImage</i> , 2012, 59, 908-916.	2.1	128
186	Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC) MRI estimates of cerebral blood volume (CBV) in human gliomas. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 1472-1477.	1.9	68
187	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. <i>Journal of Neuro-Oncology</i> , 2012, 108, 491-498.	1.4	149
188	Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. <i>Magnetic Resonance in Medicine</i> , 2012, 67, 237-245.	1.9	36
189	Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2012, 106, 111-119.	1.4	67
190	High Order Diffusion Tensor Imaging in Human Glioblastoma. <i>Academic Radiology</i> , 2011, 18, 947-954.	1.3	10
191	Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 102, 95-103.	1.4	65
192	Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2011, 105, 91-101.	1.4	33
193	Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 336-344.	2.0	98
194	Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 1131-1143.	1.9	42
195	3D visualization of subdural electrode shift as measured at craniotomy reopening. <i>Epilepsy Research</i> , 2011, 94, 102-109.	0.8	33
196	Editorial: Novel spinal cord imaging. <i>Journal of Neurosurgery: Spine</i> , 2011, 15, 645-647.	0.9	1
197	Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4482-4490.	0.8	420
198	Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 401-409.	0.6	95

#	ARTICLE	IF	CITATIONS
199	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 1151-1161.	0.6	69
200	Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. <i>Journal of Neuro-Oncology</i> , 2010, 97, 419-423.	1.4	17
201	Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 538-548.	1.9	240
202	High-resolution in vivo diffusion tensor imaging of the injured cat spinal cord using self-navigated, interleaved, variable-density spiral acquisition (SNAILS-DTI). <i>Magnetic Resonance Imaging</i> , 2010, 28, 1353-1360.	1.0	16
203	Lesion growth and degeneration patterns measured using diffusion tensor 9.4-T magnetic resonance imaging in rat spinal cord injury. <i>Journal of Neurosurgery: Spine</i> , 2010, 13, 181-192.	0.9	40
204	Morphology and Morphometry of Human Chronic Spinal Cord Injury Using Diffusion Tensor Imaging and Fuzzy Logic. <i>Annals of Biomedical Engineering</i> , 2008, 36, 224-236.	1.3	35
205	In vivo diffusion tensor imaging of the rat spinal cord at 9.4T. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 634-642.	1.9	27
206	Ex vivo diffusion tensor imaging and quantitative tractography of the rat spinal cord during long-term recovery from moderate spinal contusion. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 1068-1079.	1.9	45
207	Diffusion tensor magnetic resonance imaging in spinal cord injury. <i>Concepts in Magnetic Resonance Part A: Bridging Education and Research</i> , 2008, 32A, 219-237.	0.2	9
208	Characteristics of Mid- to Long-Latency Spinal Somatosensory Evoked Potentials following Spinal Trauma in the Rat. <i>Journal of Neurotrauma</i> , 2008, 25, 1323-1334.	1.7	6
209	Somatosensory Functional Correlates of Spinal Cord Diffusion Tensor Imaging during Long-term Recovery from Spinal Contusion. <i>Neurosurgery</i> , 2008, 62, 1411-1412.	0.6	2
210	Functional correlates of diffusion tensor imaging in spinal cord injury. <i>Biomedical Sciences Instrumentation</i> , 2008, 44, 28-33.	0.2	30
211	Gray and White Matter Delineation in the Human Spinal Cord Using Diffusion Tensor Imaging and Fuzzy Logic. <i>Academic Radiology</i> , 2007, 14, 847-858.	1.3	22
212	Optimal diffusion tensor indices for imaging the human spinal cord. <i>Biomedical Sciences Instrumentation</i> , 2007, 43, 128-33.	0.2	2
213	Morphology and Morphometry in Chronic Spinal Cord Injury Assessed Using Diffusion Tensor Imaging and Fuzzy Logic. , 2006, 2006, 1885-8.		15
214	A new technique for imaging the human spinal cord in vivo. <i>Biomedical Sciences Instrumentation</i> , 2006, 42, 255-60.	0.2	9
215	Morphology and Morphometry in Chronic Spinal Cord Injury Assessed Using Diffusion Tensor Imaging and Fuzzy Logic. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2006, , .	0.5	0